Investigational Drug Information for BAY2433334
✉ Email this page to a colleague
What is the drug development status for BAY2433334?
BAY2433334 is an investigational drug.
There have been 7 clinical trials for BAY2433334.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 15th 2022.
The most common disease conditions in clinical trials are Atrial Fibrillation, Stroke, and Ischemic Stroke. The leading clinical trial sponsors are Bayer, Population Health Research Institute, and [disabled in preview].
Summary for BAY2433334
US Patents | 0 |
International Patents | 45 |
US Patent Applications | 6 |
WIPO Patent Applications | 2 |
Japanese Patent Applications | 2 |
Clinical Trial Progress | Phase 2 (2022-12-15) |
Vendors | 21 |
Recent Clinical Trials for BAY2433334
Title | Sponsor | Phase |
---|---|---|
A Study to Learn More About Asundexian (Also Called BAY2433334) for Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older Who Already Had Such a Stroke Due to a Blood Clot That Formed Outside the Heart and Travelled t | Bayer | Phase 3 |
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke | Bayer | Phase 3 |
A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With No | Bayer | Phase 1 |
Clinical Trial Summary for BAY2433334
Top disease conditions for BAY2433334
Top clinical trial sponsors for BAY2433334
US Patents for BAY2433334
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BAY2433334
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
BAY2433334 | Argentina | AR105294 | 2035-07-09 | ⤷ Sign Up |
BAY2433334 | Australia | AU2016289746 | 2035-07-09 | ⤷ Sign Up |
BAY2433334 | Brazil | BR112018000209 | 2035-07-09 | ⤷ Sign Up |
BAY2433334 | Canada | CA2990901 | 2035-07-09 | ⤷ Sign Up |
BAY2433334 | Chile | CL2018000039 | 2035-07-09 | ⤷ Sign Up |
BAY2433334 | China | CN108026072 | 2035-07-09 | ⤷ Sign Up |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |